Evidence map›Paper›PMID 31942236›Full record

ReviewF1000Research2019

Recent advances in liver transplantation with HCV seropositive donors.

Soumya Murag, Brittany B Dennis, Donghee Kim, Aijaz Ahmed, George Cholankeril

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in F1000Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Soumya MuragDepartment of Medicine, Santa Clara Valley Medical Center, Santa Clara, CA, USA.
Brittany B DennisDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Donghee KimDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Aijaz AhmedDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
George CholankerilDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-5335-8426

Funding

TRAINING GRANT IN ACADEMIC GASTROENTEROLOGYT32DK007056 · NIDDK · STANFORD UNIVERSITY · PI Natalie J. Torok · 1986 to 2026
$6.5M
NIDDK NIH HHS T32 DK007056
6 · The paper itself

Abstract

The paradigm shift from interferon-based to direct-acting antiviral (DAA) therapy for the treatment of hepatitis C virus (HCV) infection has revolutionized the field of liver transplantation. These advances in effective HCV treatment, along with the persistent shortage in available liver grafts, have encouraged investigators to assess the need for adopting more inclusive donor policies. Owing to the poor outcomes following liver transplantation with recurrent HCV infection, liver transplantation using HCV seropositive donors (non-viremic and viremic) had been restricted. However, as a result of the growing supply of HCV seropositive donors from the recent opioid epidemic along with the advent of efficacious DAA therapy to treat HCV recurrence, there has been an increasing trend to use HCV seropositive donors for both HCV seropositive and seronegative recipients. The review aims to discuss recent advances and associated outcomes related to the use of HCV seropositive grafts for liver transplantation.

Indexed as

Liver TransplantationTissue DonorsAntiviral AgentsHepacivirusHepatitis CHumansAntiviral AgentsDAA therapyHCV donorhepatitis C virusliver transplantation

Identifiers

PMID31942236
PMCPMC6944251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.